Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-01-19

AUTHORS

Michael Rodenbach, Ergül Eyol, Matthias H. Seelig, Martin R. Berger

ABSTRACT

Purpose: The aim of this study was to evaluate the combination effect of pemetrexed disodium (MTA; Alimta; LY 231514) and gemcitabine (GEM) administered by hepatic artery and portal vein chemoembolization (HACE and PVCE) in a colorectal cancer rat liver metastasis model.Materials and methods: Proliferation studies on CC531-lac-Z rat colon cancer cells were performed using the MTT assay to obtain the optimal combination schedule of the two antineoplastic agents. To generate diffuse liver metastasis, 4×106 tumor cells were implanted into the portal vein of male WAG/Rij rats. MTA (30 mg/kg, 60 mg/kg, and 90 mg/kg) was administered locoregionally by portal vein chemoembolization (PVCE) and compared with repeated systemic intravenous injection. GEM (50 mg/kg) was also given locoregionally by hepatic artery chemoembolization (HACE) as well as systemically. All routes of administration were examined alone as well as in combination. Efficacy of treatment in terms of liver metastases burden was determined at the end of the experiment by measuring the β-galactosidase activity of CC531-lac-Z cells with a chemoluminescence assay.Results: Combination experiments in vitro showed a more than additive tumor cell reduction after sequential exposure to MTA preceding GEM (observed/expected ratio [O/E] =0.73). Experiments with the reverse sequence (GEM→MTA) resulted only in additive combination effects (O/E ratio =1.08). Simultaneous drug exposure showed less than additive combination effects (O/E ratios ≥1.25). In vivo, locoregional administration by HACE with GEM was significantly more effective than systemic intravenous bolus treatment (P=0.03). Portal vein chemoembolization with MTA performed immediately after tumor cell inoculation was ineffective. Repeated systemic treatment with MTA yielded a slight reduction in tumor cell load that was significant versus control at the medium and high doses (60 mg/kg, P=0.009; 90 mg/kg, P=0.046) but not versus intraportal chemoembolization. The combination treatment of systemic (60 and 90 mg/kg) or locoregional (60 mg/kg) MTA with HACE using GEM (50 mg/kg) resulted in more than 80% tumor growth inhibition; this antineoplastic combination effect was maximally additive.Conclusion: A regimen-dependent synergistic combination effect of both drugs was found in vitro. In animals, hepatic artery chemoembolization with GEM was superior to systemic intravenous bolus treatment. Portal vein chemoembolization with MTA was ineffective. The optimal in vitro regimen of MTA (intravenous or PVCE) preceding GEM (HACE) resulted in a maximally additive tumor growth inhibition. The results indicate that MTA and GEM can successfully be combined and favor further evaluation in patients. More... »

PAGES

289-299

References to SciGraph publications

  • 1999-07. Quantitative detection of lac-Z-transfected CC531 colon carcinoma cells in an orthotopic rat liver metastasis model in CLINICAL & EXPERIMENTAL METASTASIS
  • 2004-01-22. Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2000-05. Hepatic tumor spread of colorectal cancer in a laparoscopic animal model in SURGICAL ENDOSCOPY
  • 2000. The microscopic anatomy of experimental rat CC531 colon tumour metastases: Consequences for immunotherapy? in CLINICAL & EXPERIMENTAL METASTASIS
  • 1986-02. Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2′-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2000-07. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma in CLINICAL & EXPERIMENTAL METASTASIS
  • 1999-06. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases in LANGENBECK'S ARCHIVES OF SURGERY
  • 2000-08. Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments in MEDICAL ONCOLOGY
  • 2003-09-26. Superiority of combined chemo-embolization and portal infusion with 5-fluorouracil over locoregional infusion concepts in Novikoff hepatoma-bearing rats in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00432-004-0643-y

    DOI

    http://dx.doi.org/10.1007/s00432-004-0643-y

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1038806164

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15657768


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chemoembolization, Therapeutic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Colorectal Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Combined Modality Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Death", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Deoxycytidine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Models, Animal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glutamates", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Guanine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Metastasis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pemetrexed", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats, Inbred Strains", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.7497.d", 
              "name": [
                "Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rodenbach", 
            "givenName": "Michael", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.7497.d", 
              "name": [
                "Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Eyol", 
            "givenName": "Erg\u00fcl", 
            "id": "sg:person.0717507165.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717507165.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of General Surgery, University Clinics Muenster, Waldeyerstrasse 1, 48129, Muenster, Germany", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of General Surgery, University Clinics Muenster, Waldeyerstrasse 1, 48129, Muenster, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Seelig", 
            "givenName": "Matthias H.", 
            "id": "sg:person.01062355255.01", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062355255.01"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.7497.d", 
              "name": [
                "Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Berger", 
            "givenName": "Martin R.", 
            "id": "sg:person.01256203524.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256203524.22"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf02780523", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033622899", 
              "https://doi.org/10.1007/bf02780523"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s004230050199", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005575327", 
              "https://doi.org/10.1007/s004230050199"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s004640000159", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048957692", 
              "https://doi.org/10.1007/s004640000159"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00432-003-0495-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041271083", 
              "https://doi.org/10.1007/s00432-003-0495-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1006774602360", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001338855", 
              "https://doi.org/10.1023/a:1006774602360"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1006643831825", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015402288", 
              "https://doi.org/10.1023/a:1006643831825"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1011062002851", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036356931", 
              "https://doi.org/10.1023/a:1011062002851"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00402774", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003074278", 
              "https://doi.org/10.1007/bf00402774"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00432-003-0523-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041714068", 
              "https://doi.org/10.1007/s00432-003-0523-x"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2005-01-19", 
        "datePublishedReg": "2005-01-19", 
        "description": "Purpose: The aim of this study was to evaluate the combination effect of pemetrexed disodium (MTA; Alimta; LY\u00a0231514) and gemcitabine (GEM) administered by hepatic artery and portal vein chemoembolization (HACE and PVCE) in a colorectal cancer rat liver metastasis model.Materials and methods: Proliferation studies on CC531-lac-Z rat colon cancer cells were performed using the MTT assay to obtain the optimal combination schedule of the two antineoplastic agents. To generate diffuse liver metastasis, 4\u00d7106\u00a0tumor cells were implanted into the portal vein of male WAG/Rij rats. MTA (30\u00a0mg/kg, 60\u00a0mg/kg, and 90\u00a0mg/kg) was administered locoregionally by portal vein chemoembolization (PVCE) and compared with repeated systemic intravenous injection. GEM (50\u00a0mg/kg) was also given locoregionally by hepatic artery chemoembolization (HACE) as well as systemically. All routes of administration were examined alone as well as in combination. Efficacy of treatment in terms of liver metastases burden was determined at the end of the experiment by measuring the \u03b2-galactosidase activity of CC531-lac-Z cells with a chemoluminescence assay.Results: Combination experiments in vitro showed a more than additive tumor cell reduction after sequential exposure to MTA preceding GEM (observed/expected ratio [O/E]\u00a0=0.73). Experiments with the reverse sequence (GEM\u2192MTA) resulted only in additive combination effects (O/E\u00a0ratio\u00a0=1.08). Simultaneous drug exposure showed less than additive combination effects (O/E\u00a0ratios\u00a0\u22651.25). In vivo, locoregional administration by HACE with GEM was significantly more effective than systemic intravenous bolus treatment (P=0.03). Portal vein chemoembolization with MTA performed immediately after tumor cell inoculation was ineffective. Repeated systemic treatment with MTA yielded a slight reduction in tumor cell load that was significant versus control at the medium and high doses (60\u00a0mg/kg, P=0.009; 90\u00a0mg/kg, P=0.046) but not versus intraportal chemoembolization. The combination treatment of systemic (60\u00a0and 90\u00a0mg/kg) or locoregional (60\u00a0mg/kg) MTA with HACE using GEM (50\u00a0mg/kg) resulted in more than 80%\u00a0tumor growth inhibition; this antineoplastic combination effect was maximally additive.Conclusion: A regimen-dependent synergistic combination effect of both drugs was found in vitro. In animals, hepatic artery chemoembolization with GEM was superior to systemic intravenous bolus treatment. Portal vein chemoembolization with MTA was ineffective. The optimal in vitro regimen of MTA (intravenous or PVCE) preceding GEM (HACE) resulted in a maximally additive tumor growth inhibition. The results indicate that MTA and GEM can successfully be combined and favor further evaluation in patients.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00432-004-0643-y", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1313647", 
            "issn": [
              "0171-5216", 
              "1432-1335"
            ], 
            "name": "Journal of Cancer Research and Clinical Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "131"
          }
        ], 
        "keywords": [
          "hepatic artery chemoembolization", 
          "intravenous bolus treatment", 
          "tumor growth inhibition", 
          "additive combination effects", 
          "liver metastases", 
          "bolus treatment", 
          "combination treatment", 
          "rat liver metastasis model", 
          "additive tumor growth inhibition", 
          "optimal combination schedule", 
          "liver metastasis burden", 
          "simultaneous drug exposure", 
          "male WAG/Rij", 
          "diffuse liver metastases", 
          "tumor cell inoculation", 
          "tumor cell load", 
          "liver metastasis model", 
          "rat colon cancer cells", 
          "systemic intravenous injection", 
          "route of administration", 
          "rat liver metastases", 
          "WAG/Rij", 
          "efficacy of treatment", 
          "combination effect", 
          "growth inhibition", 
          "tumor cell reduction", 
          "metastasis burden", 
          "synergistic combination effect", 
          "systemic treatment", 
          "hepatic artery", 
          "combination schedules", 
          "portal vein", 
          "chemoluminescence assay", 
          "drug exposure", 
          "colon cancer cells", 
          "metastasis model", 
          "chemoembolization", 
          "intravenous injection", 
          "locoregional administration", 
          "cell inoculation", 
          "gemcitabine", 
          "high doses", 
          "antineoplastic agents", 
          "further evaluation", 
          "tumor cells", 
          "cell reduction", 
          "cancer cells", 
          "MTT assay", 
          "treatment", 
          "pemetrexed disodium", 
          "metastasis", 
          "administration", 
          "combination experiments", 
          "sequential exposure", 
          "proliferation studies", 
          "reverse sequence", 
          "inhibition", 
          "cells", 
          "MTA", 
          "exposure", 
          "galactosidase activity", 
          "assays", 
          "disodium", 
          "slight reduction", 
          "regimen", 
          "patients", 
          "artery", 
          "doses", 
          "efficacy", 
          "drugs", 
          "vein", 
          "effect", 
          "injection", 
          "burden", 
          "vitro", 
          "vivo", 
          "study", 
          "animals", 
          "Rij", 
          "reduction", 
          "aim", 
          "agents", 
          "cell load", 
          "inoculation", 
          "schedule", 
          "control", 
          "activity", 
          "evaluation", 
          "combination", 
          "end", 
          "route", 
          "results", 
          "method", 
          "experiments", 
          "model", 
          "materials", 
          "load", 
          "sequence", 
          "terms"
        ], 
        "name": "Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine", 
        "pagination": "289-299", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1038806164"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00432-004-0643-y"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15657768"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00432-004-0643-y", 
          "https://app.dimensions.ai/details/publication/pub.1038806164"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-06-01T22:06", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_411.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00432-004-0643-y"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0643-y'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0643-y'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0643-y'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0643-y'


     

    This table displays all metadata directly associated to this object as RDF triples.

    292 TRIPLES      22 PREDICATES      152 URIs      135 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00432-004-0643-y schema:about N12cfc35472f240139c5252626d9b04c4
    2 N154488bc61754c9b91f6906042e63dca
    3 N2abe28b7069042d4b80422ee480c28e0
    4 N2f63da647dfd4e48bde7d3b784b648b0
    5 N32036e73a9554eb685c163d7b4687195
    6 N48b5a3c08319404a9725f4c5b1c5f64b
    7 N4921ecee66604591a9ec1245df28d322
    8 N63fd79550ea24570a9a2bc01350bb816
    9 Na09b349e28734bceb858cbcb616d51bc
    10 Na83416a828dd479d9d5ae98f1a15e173
    11 Ncba491e84a6e4e7189e3ca1123bdc34c
    12 Nce5fb97ff46d4b5d8311bcd664f57348
    13 Nd5ecb39fd98c40b38282844380677866
    14 Ne21042e321a54b639d666ae508dc9c12
    15 Ne63c551ce9d9446c8dad6aa16a898cf9
    16 Nea5796175d7c446b8b653a8e948fa713
    17 Nfcf07311938d459a9737aaa0a5b2ac06
    18 Nfe0bf5d900ed43af8510eb13a8b837e3
    19 anzsrc-for:11
    20 anzsrc-for:1112
    21 schema:author Nb2adb44846f54b6f8d9f12c12c11a985
    22 schema:citation sg:pub.10.1007/bf00402774
    23 sg:pub.10.1007/bf02780523
    24 sg:pub.10.1007/s004230050199
    25 sg:pub.10.1007/s00432-003-0495-x
    26 sg:pub.10.1007/s00432-003-0523-x
    27 sg:pub.10.1007/s004640000159
    28 sg:pub.10.1023/a:1006643831825
    29 sg:pub.10.1023/a:1006774602360
    30 sg:pub.10.1023/a:1011062002851
    31 schema:datePublished 2005-01-19
    32 schema:datePublishedReg 2005-01-19
    33 schema:description Purpose: The aim of this study was to evaluate the combination effect of pemetrexed disodium (MTA; Alimta; LY 231514) and gemcitabine (GEM) administered by hepatic artery and portal vein chemoembolization (HACE and PVCE) in a colorectal cancer rat liver metastasis model.Materials and methods: Proliferation studies on CC531-lac-Z rat colon cancer cells were performed using the MTT assay to obtain the optimal combination schedule of the two antineoplastic agents. To generate diffuse liver metastasis, 4×106 tumor cells were implanted into the portal vein of male WAG/Rij rats. MTA (30 mg/kg, 60 mg/kg, and 90 mg/kg) was administered locoregionally by portal vein chemoembolization (PVCE) and compared with repeated systemic intravenous injection. GEM (50 mg/kg) was also given locoregionally by hepatic artery chemoembolization (HACE) as well as systemically. All routes of administration were examined alone as well as in combination. Efficacy of treatment in terms of liver metastases burden was determined at the end of the experiment by measuring the β-galactosidase activity of CC531-lac-Z cells with a chemoluminescence assay.Results: Combination experiments in vitro showed a more than additive tumor cell reduction after sequential exposure to MTA preceding GEM (observed/expected ratio [O/E] =0.73). Experiments with the reverse sequence (GEM→MTA) resulted only in additive combination effects (O/E ratio =1.08). Simultaneous drug exposure showed less than additive combination effects (O/E ratios ≥1.25). In vivo, locoregional administration by HACE with GEM was significantly more effective than systemic intravenous bolus treatment (P=0.03). Portal vein chemoembolization with MTA performed immediately after tumor cell inoculation was ineffective. Repeated systemic treatment with MTA yielded a slight reduction in tumor cell load that was significant versus control at the medium and high doses (60 mg/kg, P=0.009; 90 mg/kg, P=0.046) but not versus intraportal chemoembolization. The combination treatment of systemic (60 and 90 mg/kg) or locoregional (60 mg/kg) MTA with HACE using GEM (50 mg/kg) resulted in more than 80% tumor growth inhibition; this antineoplastic combination effect was maximally additive.Conclusion: A regimen-dependent synergistic combination effect of both drugs was found in vitro. In animals, hepatic artery chemoembolization with GEM was superior to systemic intravenous bolus treatment. Portal vein chemoembolization with MTA was ineffective. The optimal in vitro regimen of MTA (intravenous or PVCE) preceding GEM (HACE) resulted in a maximally additive tumor growth inhibition. The results indicate that MTA and GEM can successfully be combined and favor further evaluation in patients.
    34 schema:genre article
    35 schema:inLanguage en
    36 schema:isAccessibleForFree false
    37 schema:isPartOf N1f85dc6322714e9bb95b1142b1cbd0cc
    38 N74634b5e58a644fd806a3caf5a7fdf01
    39 sg:journal.1313647
    40 schema:keywords MTA
    41 MTT assay
    42 Rij
    43 WAG/Rij
    44 activity
    45 additive combination effects
    46 additive tumor growth inhibition
    47 administration
    48 agents
    49 aim
    50 animals
    51 antineoplastic agents
    52 artery
    53 assays
    54 bolus treatment
    55 burden
    56 cancer cells
    57 cell inoculation
    58 cell load
    59 cell reduction
    60 cells
    61 chemoembolization
    62 chemoluminescence assay
    63 colon cancer cells
    64 combination
    65 combination effect
    66 combination experiments
    67 combination schedules
    68 combination treatment
    69 control
    70 diffuse liver metastases
    71 disodium
    72 doses
    73 drug exposure
    74 drugs
    75 effect
    76 efficacy
    77 efficacy of treatment
    78 end
    79 evaluation
    80 experiments
    81 exposure
    82 further evaluation
    83 galactosidase activity
    84 gemcitabine
    85 growth inhibition
    86 hepatic artery
    87 hepatic artery chemoembolization
    88 high doses
    89 inhibition
    90 injection
    91 inoculation
    92 intravenous bolus treatment
    93 intravenous injection
    94 liver metastases
    95 liver metastasis burden
    96 liver metastasis model
    97 load
    98 locoregional administration
    99 male WAG/Rij
    100 materials
    101 metastasis
    102 metastasis burden
    103 metastasis model
    104 method
    105 model
    106 optimal combination schedule
    107 patients
    108 pemetrexed disodium
    109 portal vein
    110 proliferation studies
    111 rat colon cancer cells
    112 rat liver metastases
    113 rat liver metastasis model
    114 reduction
    115 regimen
    116 results
    117 reverse sequence
    118 route
    119 route of administration
    120 schedule
    121 sequence
    122 sequential exposure
    123 simultaneous drug exposure
    124 slight reduction
    125 study
    126 synergistic combination effect
    127 systemic intravenous injection
    128 systemic treatment
    129 terms
    130 treatment
    131 tumor cell inoculation
    132 tumor cell load
    133 tumor cell reduction
    134 tumor cells
    135 tumor growth inhibition
    136 vein
    137 vitro
    138 vivo
    139 schema:name Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine
    140 schema:pagination 289-299
    141 schema:productId N043a28f62e5d4ebdbf1c2f1ccc7f37c5
    142 N736febb6612e42478505d118cf9afb30
    143 Na662e5c538b84a4ead36e372dad32720
    144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038806164
    145 https://doi.org/10.1007/s00432-004-0643-y
    146 schema:sdDatePublished 2022-06-01T22:06
    147 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    148 schema:sdPublisher N0c95c2c5d31341f2a441255f9f0249c9
    149 schema:url https://doi.org/10.1007/s00432-004-0643-y
    150 sgo:license sg:explorer/license/
    151 sgo:sdDataset articles
    152 rdf:type schema:ScholarlyArticle
    153 N043a28f62e5d4ebdbf1c2f1ccc7f37c5 schema:name pubmed_id
    154 schema:value 15657768
    155 rdf:type schema:PropertyValue
    156 N0c95c2c5d31341f2a441255f9f0249c9 schema:name Springer Nature - SN SciGraph project
    157 rdf:type schema:Organization
    158 N12cfc35472f240139c5252626d9b04c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Pemetrexed
    160 rdf:type schema:DefinedTerm
    161 N154488bc61754c9b91f6906042e63dca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Animals
    163 rdf:type schema:DefinedTerm
    164 N199ed9a0e7534396ad792dd99501aa63 schema:affiliation grid-institutes:grid.7497.d
    165 schema:familyName Rodenbach
    166 schema:givenName Michael
    167 rdf:type schema:Person
    168 N1f85dc6322714e9bb95b1142b1cbd0cc schema:issueNumber 5
    169 rdf:type schema:PublicationIssue
    170 N2abe28b7069042d4b80422ee480c28e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Chemoembolization, Therapeutic
    172 rdf:type schema:DefinedTerm
    173 N2c83b334423c40bd8ad70ad5dbb43eab rdf:first sg:person.01062355255.01
    174 rdf:rest Nd3d4faba563d4fbb96217291c494646e
    175 N2f63da647dfd4e48bde7d3b784b648b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Rats, Inbred Strains
    177 rdf:type schema:DefinedTerm
    178 N32036e73a9554eb685c163d7b4687195 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Death
    180 rdf:type schema:DefinedTerm
    181 N48b5a3c08319404a9725f4c5b1c5f64b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Glutamates
    183 rdf:type schema:DefinedTerm
    184 N4921ecee66604591a9ec1245df28d322 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Combined Modality Therapy
    186 rdf:type schema:DefinedTerm
    187 N63fd79550ea24570a9a2bc01350bb816 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Rats
    189 rdf:type schema:DefinedTerm
    190 N736febb6612e42478505d118cf9afb30 schema:name dimensions_id
    191 schema:value pub.1038806164
    192 rdf:type schema:PropertyValue
    193 N74634b5e58a644fd806a3caf5a7fdf01 schema:volumeNumber 131
    194 rdf:type schema:PublicationVolume
    195 N93740efa74b3440cb9b4598294dbd84b rdf:first sg:person.0717507165.46
    196 rdf:rest N2c83b334423c40bd8ad70ad5dbb43eab
    197 Na09b349e28734bceb858cbcb616d51bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Antineoplastic Agents
    199 rdf:type schema:DefinedTerm
    200 Na662e5c538b84a4ead36e372dad32720 schema:name doi
    201 schema:value 10.1007/s00432-004-0643-y
    202 rdf:type schema:PropertyValue
    203 Na83416a828dd479d9d5ae98f1a15e173 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    204 schema:name Deoxycytidine
    205 rdf:type schema:DefinedTerm
    206 Nb2adb44846f54b6f8d9f12c12c11a985 rdf:first N199ed9a0e7534396ad792dd99501aa63
    207 rdf:rest N93740efa74b3440cb9b4598294dbd84b
    208 Ncba491e84a6e4e7189e3ca1123bdc34c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Male
    210 rdf:type schema:DefinedTerm
    211 Nce5fb97ff46d4b5d8311bcd664f57348 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    212 schema:name Antineoplastic Combined Chemotherapy Protocols
    213 rdf:type schema:DefinedTerm
    214 Nd3d4faba563d4fbb96217291c494646e rdf:first sg:person.01256203524.22
    215 rdf:rest rdf:nil
    216 Nd5ecb39fd98c40b38282844380677866 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Cell Line, Tumor
    218 rdf:type schema:DefinedTerm
    219 Ne21042e321a54b639d666ae508dc9c12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    220 schema:name Colorectal Neoplasms
    221 rdf:type schema:DefinedTerm
    222 Ne63c551ce9d9446c8dad6aa16a898cf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Guanine
    224 rdf:type schema:DefinedTerm
    225 Nea5796175d7c446b8b653a8e948fa713 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    226 schema:name Liver Neoplasms
    227 rdf:type schema:DefinedTerm
    228 Nfcf07311938d459a9737aaa0a5b2ac06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    229 schema:name Disease Models, Animal
    230 rdf:type schema:DefinedTerm
    231 Nfe0bf5d900ed43af8510eb13a8b837e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    232 schema:name Neoplasm Metastasis
    233 rdf:type schema:DefinedTerm
    234 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    235 schema:name Medical and Health Sciences
    236 rdf:type schema:DefinedTerm
    237 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    238 schema:name Oncology and Carcinogenesis
    239 rdf:type schema:DefinedTerm
    240 sg:journal.1313647 schema:issn 0171-5216
    241 1432-1335
    242 schema:name Journal of Cancer Research and Clinical Oncology
    243 schema:publisher Springer Nature
    244 rdf:type schema:Periodical
    245 sg:person.01062355255.01 schema:affiliation grid-institutes:None
    246 schema:familyName Seelig
    247 schema:givenName Matthias H.
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062355255.01
    249 rdf:type schema:Person
    250 sg:person.01256203524.22 schema:affiliation grid-institutes:grid.7497.d
    251 schema:familyName Berger
    252 schema:givenName Martin R.
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256203524.22
    254 rdf:type schema:Person
    255 sg:person.0717507165.46 schema:affiliation grid-institutes:grid.7497.d
    256 schema:familyName Eyol
    257 schema:givenName Ergül
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717507165.46
    259 rdf:type schema:Person
    260 sg:pub.10.1007/bf00402774 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003074278
    261 https://doi.org/10.1007/bf00402774
    262 rdf:type schema:CreativeWork
    263 sg:pub.10.1007/bf02780523 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033622899
    264 https://doi.org/10.1007/bf02780523
    265 rdf:type schema:CreativeWork
    266 sg:pub.10.1007/s004230050199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005575327
    267 https://doi.org/10.1007/s004230050199
    268 rdf:type schema:CreativeWork
    269 sg:pub.10.1007/s00432-003-0495-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041271083
    270 https://doi.org/10.1007/s00432-003-0495-x
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1007/s00432-003-0523-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041714068
    273 https://doi.org/10.1007/s00432-003-0523-x
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.1007/s004640000159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048957692
    276 https://doi.org/10.1007/s004640000159
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.1023/a:1006643831825 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015402288
    279 https://doi.org/10.1023/a:1006643831825
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1023/a:1006774602360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001338855
    282 https://doi.org/10.1023/a:1006774602360
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1023/a:1011062002851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036356931
    285 https://doi.org/10.1023/a:1011062002851
    286 rdf:type schema:CreativeWork
    287 grid-institutes:None schema:alternateName Department of General Surgery, University Clinics Muenster, Waldeyerstrasse 1, 48129, Muenster, Germany
    288 schema:name Department of General Surgery, University Clinics Muenster, Waldeyerstrasse 1, 48129, Muenster, Germany
    289 rdf:type schema:Organization
    290 grid-institutes:grid.7497.d schema:alternateName Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany
    291 schema:name Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 120, 69120, Heidelberg, Germany
    292 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...